Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Craniotomy, Cesium-131 brachytherapy · 1 trial · 1 indication
With a contrast enhanced brain MRI scan. Treatment response will be determined based on the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria.
| Arm | Type | Description |
|---|---|---|
| Resection without brachytherapy | ACTIVE_COMPARATOR | Patients will undergo craniotomy. |
| Resection plus brachytherapy | EXPERIMENTAL | Patients will undergo craniotomy and patients in the treatment arm will undergo implantation of Cesium 131 brachytherapy in coordination with the radiation oncologist. |
| Name | Type | Description |
|---|---|---|
| Craniotomy | PROCEDURE | Craniotomy |
| Cesium-131 brachytherapy | RADIATION | Intracavitary Cesium-131 brachytherapy |
Inclusion Criteria: * Adult patients ≥ 18 years of age who are capable of giving consent * Undergoing elective craniotomy for resection of a previously-irradiated brain metastasis with suspicion for viable disease at the time of consent, and anticipated achievement of gross-total or near-total (\>/...
Craniotomy, Cesium-131 brachytherapy is used for recurrent brain metastases. It is an investigational treatment being studied in a Phase 2 clinical trial for patients with this condition.
GT Biopharma, Inc. (ticker: GTBP) is developing Craniotomy, Cesium-131 brachytherapy. The company is conducting a Phase 2 clinical trial to evaluate this treatment for recurrent brain metastases.
Craniotomy, Cesium-131 brachytherapy is in Phase 2 clinical development. It is an investigational treatment and has not been approved by the FDA for recurrent brain metastases.
Craniotomy, Cesium-131 brachytherapy is being studied in trial NCT04690348, titled 'Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study.' This trial is recruiting 103 participants in the United States.
Yes, the Phase 2 clinical trial for Craniotomy, Cesium-131 brachytherapy is randomized and active-controlled. It is not double-blind, and it uses biomarker selection for patient enrollment.